Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Checklist | 30 | 2024 | 827 | 3.550 |
Why?
|
Operating Rooms | 20 | 2024 | 789 | 2.600 |
Why?
|
Surgical Procedures, Operative | 22 | 2018 | 1924 | 1.790 |
Why?
|
Patient Care Team | 16 | 2021 | 2515 | 1.670 |
Why?
|
Taxoids | 13 | 2016 | 667 | 1.230 |
Why?
|
Neoplasms, Hormone-Dependent | 5 | 2006 | 410 | 0.850 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 23 | 2023 | 11736 | 0.840 |
Why?
|
Safety Management | 9 | 2018 | 760 | 0.840 |
Why?
|
Prednisone | 13 | 2022 | 1562 | 0.790 |
Why?
|
Quality Improvement | 8 | 2019 | 3797 | 0.770 |
Why?
|
Interprofessional Relations | 6 | 2019 | 990 | 0.730 |
Why?
|
Prostatic Neoplasms | 25 | 2020 | 11106 | 0.720 |
Why?
|
South Carolina | 8 | 2018 | 100 | 0.700 |
Why?
|
Prostate-Specific Antigen | 20 | 2022 | 2465 | 0.690 |
Why?
|
Surgery Department, Hospital | 4 | 2015 | 176 | 0.640 |
Why?
|
Phenylthiohydantoin | 4 | 2023 | 205 | 0.610 |
Why?
|
Health Systems Plans | 1 | 2017 | 19 | 0.570 |
Why?
|
Cyclosporine | 1 | 2020 | 778 | 0.570 |
Why?
|
Antineoplastic Agents, Hormonal | 6 | 2020 | 1520 | 0.550 |
Why?
|
Jurisprudence | 1 | 2017 | 109 | 0.550 |
Why?
|
Commitment of Mentally Ill | 1 | 2017 | 94 | 0.550 |
Why?
|
Postoperative Complications | 15 | 2017 | 15612 | 0.530 |
Why?
|
Dermatologic Agents | 1 | 2020 | 313 | 0.520 |
Why?
|
Civil Rights | 1 | 2017 | 132 | 0.520 |
Why?
|
Hospital Mortality | 10 | 2017 | 5293 | 0.500 |
Why?
|
Medical Errors | 6 | 2018 | 1263 | 0.490 |
Why?
|
Emergency Treatment | 2 | 2018 | 495 | 0.490 |
Why?
|
Tissue Extracts | 1 | 2015 | 139 | 0.480 |
Why?
|
Developed Countries | 2 | 2017 | 450 | 0.470 |
Why?
|
Patient Advocacy | 1 | 2017 | 360 | 0.470 |
Why?
|
General Surgery | 7 | 2019 | 1692 | 0.460 |
Why?
|
Intraoperative Complications | 4 | 2017 | 1161 | 0.460 |
Why?
|
Clinical Protocols | 2 | 2018 | 1437 | 0.440 |
Why?
|
Hospitals | 9 | 2020 | 3877 | 0.440 |
Why?
|
Prisoners | 1 | 2017 | 314 | 0.440 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1745 | 0.430 |
Why?
|
World Health Organization | 12 | 2018 | 1321 | 0.420 |
Why?
|
Labor, Obstetric | 3 | 2022 | 323 | 0.420 |
Why?
|
Mitoxantrone | 5 | 2012 | 148 | 0.400 |
Why?
|
Psoriasis | 1 | 2020 | 944 | 0.390 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1333 | 0.390 |
Why?
|
Advanced Cardiac Life Support | 1 | 2012 | 78 | 0.380 |
Why?
|
Benchmarking | 1 | 2017 | 1045 | 0.360 |
Why?
|
Communication | 8 | 2024 | 3849 | 0.360 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2008 | 782 | 0.350 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2020 | 1727 | 0.330 |
Why?
|
Nitriles | 4 | 2023 | 971 | 0.330 |
Why?
|
Androgen Antagonists | 6 | 2022 | 1409 | 0.330 |
Why?
|
Organizational Culture | 1 | 2013 | 509 | 0.320 |
Why?
|
Electric Countershock | 1 | 2012 | 532 | 0.320 |
Why?
|
Benzamides | 4 | 2023 | 1371 | 0.320 |
Why?
|
Urothelium | 2 | 2008 | 269 | 0.310 |
Why?
|
Androstenes | 2 | 2021 | 181 | 0.310 |
Why?
|
Interdisciplinary Communication | 4 | 2012 | 928 | 0.310 |
Why?
|
Malpractice | 2 | 2019 | 556 | 0.300 |
Why?
|
Organizations, Nonprofit | 1 | 2008 | 105 | 0.300 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1998 | 0.300 |
Why?
|
Estramustine | 4 | 2007 | 35 | 0.270 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1386 | 0.270 |
Why?
|
Pancreatic Neoplasms | 3 | 2021 | 5367 | 0.270 |
Why?
|
Musculoskeletal System | 1 | 2008 | 188 | 0.260 |
Why?
|
Adenocarcinoma | 7 | 2012 | 6340 | 0.260 |
Why?
|
Oximetry | 3 | 2015 | 459 | 0.250 |
Why?
|
Neoplasm Metastasis | 10 | 2023 | 4910 | 0.250 |
Why?
|
Guideline Adherence | 7 | 2016 | 2218 | 0.250 |
Why?
|
Humans | 115 | 2024 | 760617 | 0.250 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2021 | 943 | 0.250 |
Why?
|
Practice Management, Medical | 1 | 2007 | 191 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2019 | 5304 | 0.240 |
Why?
|
Perioperative Care | 1 | 2012 | 1037 | 0.240 |
Why?
|
Risk Management | 2 | 2019 | 557 | 0.240 |
Why?
|
Liability, Legal | 1 | 2006 | 210 | 0.240 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2008 | 2223 | 0.230 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2012 | 992 | 0.230 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 9172 | 0.230 |
Why?
|
Program Evaluation | 4 | 2018 | 2486 | 0.220 |
Why?
|
Drug Administration Schedule | 5 | 2009 | 4845 | 0.220 |
Why?
|
Clinical Competence | 7 | 2019 | 4789 | 0.220 |
Why?
|
Aged, 80 and over | 25 | 2023 | 58894 | 0.210 |
Why?
|
Treatment Outcome | 26 | 2022 | 64568 | 0.200 |
Why?
|
Male | 66 | 2023 | 360358 | 0.200 |
Why?
|
Quality of Health Care | 4 | 2013 | 4321 | 0.200 |
Why?
|
Heart Arrest | 1 | 2012 | 1513 | 0.200 |
Why?
|
International Cooperation | 1 | 2008 | 1421 | 0.200 |
Why?
|
Developing Countries | 4 | 2013 | 2867 | 0.190 |
Why?
|
Program Development | 4 | 2019 | 1293 | 0.190 |
Why?
|
Quality Assurance, Health Care | 6 | 2017 | 2164 | 0.190 |
Why?
|
Aged | 42 | 2023 | 169042 | 0.190 |
Why?
|
Wounds and Injuries | 2 | 2017 | 2491 | 0.180 |
Why?
|
Education, Medical, Continuing | 2 | 2019 | 823 | 0.180 |
Why?
|
Nausea | 3 | 2020 | 679 | 0.180 |
Why?
|
Kallikreins | 2 | 2019 | 220 | 0.180 |
Why?
|
Cognition | 1 | 2018 | 6987 | 0.180 |
Why?
|
Organizational Innovation | 3 | 2013 | 537 | 0.170 |
Why?
|
Hospital Administration | 2 | 2014 | 353 | 0.170 |
Why?
|
Chromosomal Instability | 1 | 2021 | 178 | 0.170 |
Why?
|
Leadership | 4 | 2018 | 1385 | 0.170 |
Why?
|
Antineoplastic Agents | 9 | 2019 | 13635 | 0.170 |
Why?
|
Middle Aged | 42 | 2023 | 220584 | 0.170 |
Why?
|
Health Resources | 2 | 2018 | 933 | 0.170 |
Why?
|
Orthopedics | 1 | 2008 | 898 | 0.170 |
Why?
|
Education, Nursing, Continuing | 1 | 2019 | 69 | 0.160 |
Why?
|
Disease-Free Survival | 11 | 2022 | 6807 | 0.160 |
Why?
|
Delivery of Health Care | 3 | 2018 | 5332 | 0.160 |
Why?
|
Androgen Receptor Antagonists | 2 | 2018 | 125 | 0.160 |
Why?
|
Medical Staff, Hospital | 3 | 2017 | 601 | 0.160 |
Why?
|
Retinal Dehydrogenase | 1 | 2018 | 78 | 0.160 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2018 | 88 | 0.160 |
Why?
|
Qualitative Research | 2 | 2020 | 3016 | 0.150 |
Why?
|
Australia | 2 | 2020 | 1248 | 0.150 |
Why?
|
Critical Care | 4 | 2017 | 2690 | 0.150 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2018 | 146 | 0.150 |
Why?
|
Paracentesis | 1 | 2018 | 98 | 0.150 |
Why?
|
Manuals as Topic | 1 | 2017 | 99 | 0.150 |
Why?
|
Health Plan Implementation | 2 | 2018 | 335 | 0.140 |
Why?
|
Attitude of Health Personnel | 5 | 2019 | 3879 | 0.140 |
Why?
|
Clinical Trials as Topic | 5 | 2011 | 7995 | 0.140 |
Why?
|
Mutation | 3 | 2021 | 30016 | 0.140 |
Why?
|
Judicial Role | 1 | 2017 | 38 | 0.140 |
Why?
|
Survival Analysis | 9 | 2019 | 10073 | 0.140 |
Why?
|
Dangerous Behavior | 1 | 2017 | 65 | 0.140 |
Why?
|
Azacitidine | 2 | 2009 | 335 | 0.140 |
Why?
|
Oregon | 1 | 2017 | 147 | 0.140 |
Why?
|
Surgical Instruments | 1 | 2019 | 383 | 0.140 |
Why?
|
Castration | 4 | 2011 | 151 | 0.140 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 2689 | 0.140 |
Why?
|
Survival Rate | 8 | 2017 | 12719 | 0.140 |
Why?
|
Thiohydantoins | 1 | 2016 | 19 | 0.130 |
Why?
|
Hospital Units | 1 | 2017 | 142 | 0.130 |
Why?
|
Health Services Research | 2 | 2018 | 1808 | 0.130 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 3593 | 0.130 |
Why?
|
Surgicenters | 1 | 2016 | 50 | 0.130 |
Why?
|
Maternal Mortality | 2 | 2015 | 301 | 0.130 |
Why?
|
Personnel, Hospital | 1 | 2017 | 285 | 0.120 |
Why?
|
Carcinoma | 1 | 2007 | 2327 | 0.120 |
Why?
|
Equipment Safety | 1 | 2016 | 249 | 0.120 |
Why?
|
Enzyme Inhibitors | 3 | 2018 | 3705 | 0.120 |
Why?
|
Gossypol | 2 | 2012 | 23 | 0.120 |
Why?
|
Feedback | 2 | 2017 | 790 | 0.120 |
Why?
|
Cooperative Behavior | 2 | 2016 | 1504 | 0.120 |
Why?
|
Orchiectomy | 3 | 2012 | 463 | 0.120 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2016 | 195 | 0.120 |
Why?
|
Alternative Splicing | 1 | 2020 | 1088 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2017 | 349 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2009 | 645 | 0.120 |
Why?
|
Patient Simulation | 2 | 2014 | 298 | 0.120 |
Why?
|
Prognosis | 9 | 2017 | 29600 | 0.120 |
Why?
|
Paclitaxel | 3 | 2007 | 1730 | 0.120 |
Why?
|
Renal Insufficiency | 1 | 2020 | 808 | 0.120 |
Why?
|
Intraoperative Care | 1 | 2018 | 767 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2011 | 10199 | 0.110 |
Why?
|
Androstenols | 1 | 2013 | 25 | 0.110 |
Why?
|
Female | 35 | 2022 | 392148 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2017 | 1703 | 0.110 |
Why?
|
Health Services Accessibility | 4 | 2013 | 5430 | 0.110 |
Why?
|
Risk Adjustment | 1 | 2017 | 599 | 0.110 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3680 | 0.110 |
Why?
|
Treatment Refusal | 1 | 2017 | 429 | 0.110 |
Why?
|
Carboplatin | 2 | 2007 | 793 | 0.110 |
Why?
|
Infant Mortality | 2 | 2015 | 751 | 0.110 |
Why?
|
Drug Design | 1 | 2018 | 1045 | 0.110 |
Why?
|
Renal Replacement Therapy | 1 | 2015 | 281 | 0.110 |
Why?
|
Financial Management, Hospital | 1 | 2013 | 70 | 0.100 |
Why?
|
Adult | 24 | 2021 | 220969 | 0.100 |
Why?
|
Social Behavior | 1 | 2019 | 1135 | 0.100 |
Why?
|
Receptors, Androgen | 1 | 2019 | 1079 | 0.100 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1827 | 0.100 |
Why?
|
Cancer Vaccines | 2 | 2013 | 1037 | 0.100 |
Why?
|
Manikins | 1 | 2014 | 244 | 0.100 |
Why?
|
Patient Care | 1 | 2018 | 621 | 0.100 |
Why?
|
Emergency Service, Hospital | 3 | 2018 | 7871 | 0.100 |
Why?
|
Insurance Carriers | 1 | 2014 | 155 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2017 | 1380 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1255 | 0.100 |
Why?
|
Postoperative Care | 2 | 2016 | 1467 | 0.100 |
Why?
|
Mice, SCID | 1 | 2017 | 2625 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2019 | 10754 | 0.100 |
Why?
|
Diagnosis-Related Groups | 1 | 2013 | 448 | 0.090 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2016 | 463 | 0.090 |
Why?
|
Internationality | 3 | 2016 | 1000 | 0.090 |
Why?
|
Neoadjuvant Therapy | 3 | 2007 | 2827 | 0.090 |
Why?
|
Thalidomide | 1 | 2016 | 885 | 0.090 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2006 | 620 | 0.090 |
Why?
|
Cisplatin | 2 | 2008 | 1650 | 0.090 |
Why?
|
Medication Errors | 1 | 2017 | 783 | 0.090 |
Why?
|
Physician-Patient Relations | 2 | 2019 | 3239 | 0.090 |
Why?
|
Research Design | 1 | 2006 | 6174 | 0.090 |
Why?
|
Adolescent | 11 | 2020 | 88234 | 0.090 |
Why?
|
Cesarean Section | 2 | 2017 | 1396 | 0.090 |
Why?
|
Health Personnel | 4 | 2017 | 3333 | 0.090 |
Why?
|
Outpatients | 1 | 2018 | 1596 | 0.090 |
Why?
|
Delivery, Obstetric | 1 | 2017 | 939 | 0.090 |
Why?
|
Young Adult | 7 | 2020 | 59179 | 0.090 |
Why?
|
Propensity Score | 1 | 2017 | 1911 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11116 | 0.080 |
Why?
|
Calcitriol | 1 | 2011 | 296 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2017 | 1835 | 0.080 |
Why?
|
Blood Coagulation | 1 | 2015 | 1154 | 0.080 |
Why?
|
Cost Sharing | 1 | 2013 | 409 | 0.080 |
Why?
|
Blotting, Western | 1 | 2017 | 5034 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 206 | 0.080 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6126 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 7389 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 1529 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1167 | 0.080 |
Why?
|
Hospitals, Community | 1 | 2011 | 365 | 0.080 |
Why?
|
Heparin | 1 | 2015 | 1632 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4739 | 0.080 |
Why?
|
Doxorubicin | 2 | 2006 | 2224 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2011 | 9277 | 0.070 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1926 | 0.070 |
Why?
|
Pilot Projects | 6 | 2019 | 8618 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39063 | 0.070 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3419 | 0.070 |
Why?
|
Emergency Medical Services | 2 | 2017 | 1921 | 0.070 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2009 | 330 | 0.070 |
Why?
|
Maternal Health Services | 1 | 2013 | 460 | 0.070 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2009 | 264 | 0.070 |
Why?
|
Child Health Services | 1 | 2013 | 644 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2020 | 10432 | 0.070 |
Why?
|
Liver Diseases | 1 | 2016 | 1297 | 0.070 |
Why?
|
Alkaline Phosphatase | 1 | 2010 | 860 | 0.070 |
Why?
|
Esophagectomy | 1 | 2011 | 467 | 0.070 |
Why?
|
Neutropenia | 1 | 2012 | 885 | 0.070 |
Why?
|
Exanthema | 1 | 2012 | 503 | 0.070 |
Why?
|
Hospital Costs | 1 | 2013 | 947 | 0.070 |
Why?
|
United States | 11 | 2018 | 72272 | 0.070 |
Why?
|
Guanine | 1 | 2008 | 278 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8542 | 0.070 |
Why?
|
Mythology | 1 | 2006 | 15 | 0.070 |
Why?
|
Glutamates | 1 | 2008 | 389 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 2921 | 0.070 |
Why?
|
Consent Forms | 1 | 2006 | 55 | 0.070 |
Why?
|
Health Care Surveys | 4 | 2017 | 2423 | 0.070 |
Why?
|
Time Factors | 5 | 2020 | 39913 | 0.070 |
Why?
|
Benzenesulfonates | 1 | 2006 | 166 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2011 | 857 | 0.060 |
Why?
|
Vitamin B Complex | 1 | 2008 | 299 | 0.060 |
Why?
|
Chlorambucil | 1 | 2005 | 42 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2011 | 969 | 0.060 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 883 | 0.060 |
Why?
|
Lomustine | 1 | 2005 | 60 | 0.060 |
Why?
|
Workload | 1 | 2011 | 844 | 0.060 |
Why?
|
Cost Savings | 1 | 2010 | 912 | 0.060 |
Why?
|
Vitamin B 12 | 1 | 2008 | 524 | 0.060 |
Why?
|
Protein Isoforms | 2 | 2020 | 1697 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 488 | 0.060 |
Why?
|
Internship and Residency | 3 | 2011 | 5878 | 0.060 |
Why?
|
Physicians | 2 | 2020 | 4583 | 0.060 |
Why?
|
Retrospective Studies | 14 | 2021 | 80566 | 0.060 |
Why?
|
Niacinamide | 1 | 2006 | 413 | 0.060 |
Why?
|
Colectomy | 1 | 2009 | 686 | 0.060 |
Why?
|
Hemorrhage | 1 | 2016 | 3418 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8207 | 0.060 |
Why?
|
Hematologic Diseases | 1 | 2008 | 496 | 0.060 |
Why?
|
Length of Stay | 2 | 2015 | 6418 | 0.060 |
Why?
|
Healthcare Disparities | 2 | 2010 | 3351 | 0.060 |
Why?
|
Uganda | 1 | 2008 | 1332 | 0.050 |
Why?
|
Deoxycytidine | 1 | 2008 | 878 | 0.050 |
Why?
|
Phenylurea Compounds | 1 | 2006 | 529 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2006 | 458 | 0.050 |
Why?
|
Hospitalization | 3 | 2018 | 10704 | 0.050 |
Why?
|
Inpatients | 2 | 2011 | 2544 | 0.050 |
Why?
|
Clostridium Infections | 1 | 2009 | 557 | 0.050 |
Why?
|
Academic Medical Centers | 2 | 2011 | 2756 | 0.050 |
Why?
|
Area Under Curve | 1 | 2007 | 1635 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2005 | 629 | 0.050 |
Why?
|
Prospective Studies | 8 | 2021 | 54360 | 0.050 |
Why?
|
Infection Control | 1 | 2009 | 982 | 0.050 |
Why?
|
Education, Medical | 1 | 2014 | 1724 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15828 | 0.050 |
Why?
|
Pyrroles | 1 | 2008 | 1125 | 0.050 |
Why?
|
Treatment Failure | 2 | 2011 | 2635 | 0.050 |
Why?
|
Medical Oncology | 1 | 2013 | 2317 | 0.050 |
Why?
|
Bone Neoplasms | 2 | 2011 | 2527 | 0.050 |
Why?
|
Health Policy | 2 | 2011 | 2682 | 0.050 |
Why?
|
Prostatectomy | 2 | 2007 | 1824 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2020 | 2925 | 0.050 |
Why?
|
Vincristine | 1 | 2003 | 1036 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9417 | 0.050 |
Why?
|
Folic Acid | 1 | 2008 | 1323 | 0.050 |
Why?
|
Apoptosis | 1 | 2017 | 9476 | 0.050 |
Why?
|
Cause of Death | 1 | 2011 | 3683 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1653 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2024 | 20074 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2003 | 629 | 0.040 |
Why?
|
Seminal Vesicles | 1 | 2020 | 103 | 0.040 |
Why?
|
Interviews as Topic | 3 | 2013 | 2697 | 0.040 |
Why?
|
Cross Infection | 1 | 2009 | 1422 | 0.040 |
Why?
|
Indoles | 1 | 2008 | 1830 | 0.040 |
Why?
|
Physician's Role | 1 | 2007 | 917 | 0.040 |
Why?
|
Hypertension | 1 | 2020 | 8529 | 0.040 |
Why?
|
Anticoagulants | 1 | 2015 | 4785 | 0.040 |
Why?
|
Patient Discharge | 1 | 2013 | 3442 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5239 | 0.040 |
Why?
|
Operating Room Nursing | 1 | 2019 | 25 | 0.040 |
Why?
|
Neurosecretory Systems | 1 | 2021 | 223 | 0.040 |
Why?
|
Pregnancy | 5 | 2022 | 29868 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 26049 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1790 | 0.040 |
Why?
|
Methotrexate | 1 | 2006 | 1716 | 0.040 |
Why?
|
Africa South of the Sahara | 2 | 2013 | 745 | 0.040 |
Why?
|
Infant | 3 | 2016 | 36152 | 0.040 |
Why?
|
Peer Review, Health Care | 1 | 2019 | 73 | 0.040 |
Why?
|
Probability | 1 | 2004 | 2475 | 0.040 |
Why?
|
MutS Homolog 2 Protein | 1 | 2019 | 197 | 0.040 |
Why?
|
Thailand | 1 | 2019 | 287 | 0.040 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2018 | 99 | 0.040 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 15251 | 0.040 |
Why?
|
Emergencies | 2 | 2017 | 1217 | 0.040 |
Why?
|
Pediatrics | 1 | 2013 | 3588 | 0.040 |
Why?
|
Primary Nursing | 1 | 2017 | 10 | 0.040 |
Why?
|
Protective Clothing | 1 | 2018 | 103 | 0.040 |
Why?
|
Population Surveillance | 1 | 2008 | 2595 | 0.040 |
Why?
|
Dexamethasone | 1 | 2005 | 1947 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3514 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2003 | 2218 | 0.040 |
Why?
|
Quality of Life | 5 | 2020 | 13347 | 0.040 |
Why?
|
Logistic Models | 3 | 2010 | 13245 | 0.040 |
Why?
|
Sterilization | 1 | 2018 | 132 | 0.040 |
Why?
|
Reference Values | 1 | 2004 | 4919 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2020 | 552 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 1 | 2012 | 3621 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2019 | 488 | 0.030 |
Why?
|
Cell Movement | 2 | 2020 | 5200 | 0.030 |
Why?
|
Chickens | 1 | 2018 | 858 | 0.030 |
Why?
|
Nurses | 2 | 2018 | 2477 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 3 | 2012 | 6474 | 0.030 |
Why?
|
Ethiopia | 1 | 2018 | 460 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2003 | 1372 | 0.030 |
Why?
|
Infant, Newborn | 4 | 2022 | 26180 | 0.030 |
Why?
|
Child, Preschool | 2 | 2016 | 42188 | 0.030 |
Why?
|
Moldova | 1 | 2015 | 14 | 0.030 |
Why?
|
Anti-Infective Agents, Local | 1 | 2018 | 247 | 0.030 |
Why?
|
DNA Methylation | 1 | 2009 | 4391 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14018 | 0.030 |
Why?
|
Pharmacists | 1 | 2017 | 258 | 0.030 |
Why?
|
Pyridines | 1 | 2006 | 2874 | 0.030 |
Why?
|
Massachusetts | 2 | 2019 | 8833 | 0.030 |
Why?
|
Perioperative Period | 1 | 2016 | 250 | 0.030 |
Why?
|
Systems Integration | 1 | 2016 | 426 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6305 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2019 | 664 | 0.030 |
Why?
|
Molecular Structure | 1 | 2018 | 1878 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2016 | 381 | 0.030 |
Why?
|
Radiography | 2 | 2018 | 6961 | 0.030 |
Why?
|
Mice | 2 | 2020 | 81368 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 649 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2016 | 843 | 0.030 |
Why?
|
Nursing Staff, Hospital | 1 | 2017 | 348 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8516 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 780 | 0.030 |
Why?
|
Oligopeptides | 1 | 2019 | 1185 | 0.030 |
Why?
|
Hospitals, Voluntary | 1 | 2013 | 39 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2018 | 1155 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2018 | 3074 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4110 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 637 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5866 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2019 | 960 | 0.030 |
Why?
|
Child | 3 | 2016 | 80079 | 0.030 |
Why?
|
Zambia | 1 | 2013 | 262 | 0.030 |
Why?
|
France | 1 | 2013 | 492 | 0.030 |
Why?
|
Life Expectancy | 2 | 2010 | 1239 | 0.030 |
Why?
|
Animals | 3 | 2020 | 168201 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2006 | 3164 | 0.020 |
Why?
|
Malignant Hyperthermia | 1 | 2011 | 71 | 0.020 |
Why?
|
North America | 1 | 2015 | 1273 | 0.020 |
Why?
|
Early Termination of Clinical Trials | 1 | 2011 | 67 | 0.020 |
Why?
|
Persuasive Communication | 1 | 2011 | 58 | 0.020 |
Why?
|
Ownership | 1 | 2013 | 339 | 0.020 |
Why?
|
Family | 1 | 2022 | 3193 | 0.020 |
Why?
|
Embolism, Air | 1 | 2011 | 109 | 0.020 |
Why?
|
Kinetics | 1 | 2018 | 6370 | 0.020 |
Why?
|
Group Processes | 1 | 2012 | 228 | 0.020 |
Why?
|
Disease Progression | 2 | 2009 | 13495 | 0.020 |
Why?
|
Africa, Northern | 1 | 2010 | 86 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3599 | 0.020 |
Why?
|
Washington | 1 | 2011 | 315 | 0.020 |
Why?
|
Medicare | 3 | 2014 | 6765 | 0.020 |
Why?
|
Aviation | 1 | 2010 | 49 | 0.020 |
Why?
|
Housekeeping, Hospital | 1 | 2009 | 17 | 0.020 |
Why?
|
Private Sector | 1 | 2013 | 394 | 0.020 |
Why?
|
Testosterone | 1 | 2020 | 2472 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2006 | 4250 | 0.020 |
Why?
|
Middle East | 1 | 2010 | 231 | 0.020 |
Why?
|
New Zealand | 1 | 2010 | 358 | 0.020 |
Why?
|
Curriculum | 2 | 2014 | 3738 | 0.020 |
Why?
|
Insurance Claim Review | 1 | 2014 | 741 | 0.020 |
Why?
|
Orthopedic Procedures | 1 | 2019 | 1265 | 0.020 |
Why?
|
Perception | 1 | 2016 | 1198 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4269 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1149 | 0.020 |
Why?
|
Latin America | 1 | 2010 | 407 | 0.020 |
Why?
|
Autophagy | 1 | 2017 | 1326 | 0.020 |
Why?
|
Decision Making | 2 | 2013 | 3918 | 0.020 |
Why?
|
Poverty Areas | 1 | 2010 | 263 | 0.020 |
Why?
|
Postpartum Period | 1 | 2015 | 1178 | 0.020 |
Why?
|
Asia | 1 | 2010 | 615 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12043 | 0.020 |
Why?
|
Inservice Training | 1 | 2011 | 375 | 0.020 |
Why?
|
Models, Molecular | 1 | 2018 | 5433 | 0.020 |
Why?
|
Databases, Factual | 2 | 2016 | 7960 | 0.020 |
Why?
|
Risk Factors | 4 | 2017 | 74115 | 0.020 |
Why?
|
Medically Underserved Area | 1 | 2010 | 254 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2009 | 407 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2013 | 542 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2016 | 1496 | 0.020 |
Why?
|
Hospitals, University | 1 | 2009 | 564 | 0.020 |
Why?
|
Risk Assessment | 2 | 2011 | 23972 | 0.020 |
Why?
|
Fatigue | 1 | 2015 | 1550 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 2178 | 0.020 |
Why?
|
Boston | 2 | 2011 | 9313 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2013 | 909 | 0.020 |
Why?
|
Policy Making | 1 | 2011 | 541 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3868 | 0.020 |
Why?
|
DNA Damage | 1 | 2017 | 2446 | 0.020 |
Why?
|
Hospitals, General | 1 | 2011 | 798 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 3577 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3451 | 0.020 |
Why?
|
Sex Distribution | 1 | 2011 | 2278 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14648 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2009 | 414 | 0.020 |
Why?
|
Counseling | 1 | 2014 | 1538 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41457 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2010 | 697 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2871 | 0.020 |
Why?
|
Canada | 1 | 2010 | 2118 | 0.010 |
Why?
|
Constipation | 1 | 2009 | 563 | 0.010 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 526 | 0.010 |
Why?
|
Device Removal | 1 | 2009 | 629 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2011 | 1263 | 0.010 |
Why?
|
Incidence | 2 | 2015 | 21337 | 0.010 |
Why?
|
Anaphylaxis | 1 | 2011 | 757 | 0.010 |
Why?
|
Health Expenditures | 1 | 2016 | 2361 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16571 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 18937 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2009 | 1299 | 0.010 |
Why?
|
Diarrhea | 1 | 2009 | 1317 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2010 | 1400 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2009 | 1182 | 0.010 |
Why?
|
Income | 1 | 2010 | 1870 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 4010 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 2234 | 0.010 |
Why?
|
Insurance, Health | 1 | 2013 | 2495 | 0.010 |
Why?
|
Regression Analysis | 1 | 2010 | 6338 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16967 | 0.010 |
Why?
|
Data Collection | 1 | 2009 | 3315 | 0.010 |
Why?
|
Anemia | 1 | 2009 | 1504 | 0.010 |
Why?
|
Medicaid | 1 | 2013 | 2814 | 0.010 |
Why?
|
Odds Ratio | 1 | 2011 | 9643 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6233 | 0.010 |
Why?
|
Immunotherapy | 1 | 2013 | 4642 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14591 | 0.010 |
Why?
|
Critical Illness | 1 | 2009 | 2709 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12447 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 12334 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20556 | 0.010 |
Why?
|
Age Factors | 1 | 2003 | 18381 | 0.000 |
Why?
|